Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Zimmer, Lisa; Apuri, Susmitha; Eroglu, Zeynep; Kottschade, Lisa A.; Forschner, Andrea; Gutzmer, Ralf; Schlaak, Max; Heinzerling, Lucie; Krackhardt, Angela M.; Loquai, Carmen; Markovic, Svetomir N.; Joseph, Richard W.; Markey, Kelly; Utikal, Jochen; Weishaupt, Carsten; Goldinger, Simone M.; Sondak, Vernon K.; Zager, Jonathan S.; Schadendorf, Dirk; Khushalani, Nikhil I.

doi:10.1016/j.ejca.2017.01.009

Cited by 151 publications

(139 citation statements)

References 23 publications

Supporting

Mentioning

129

Contrasting

Unclassified

Order By: Relevance

“…The phase II Keynote 024 and Anti-PD1 Brain Collaboration (ABC) trials of nivolumab and ipilimumab in combination also showed their effectiveness and safety in melanoma with brain metastasis. In second-line settings, ipilimumab alone had a better PFS compared to ipilimumab plus nivolumab, in patients with advanced melanoma after treatment failure on anti-PD-1 [53]. As expected, nivolumab led to a better objective response and fewer toxic effects than alternative chemotherapy in patients with advanced melanoma that progressed after ipilimumab or ipilimumab and a BRAF inhibitor [54].…”

Section: Discussionmentioning

confidence: 99%

Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

Gbadamosi

Ezekwudo

Nayak

et al. 2018

Case Reports in Immunology

View full text Add to dashboard Cite

Malignant melanoma is responsible for the majority of skin cancer deaths and is increasing in prevalence. Bone marrow (BM) involvement by melanoma is rare in the absence of widespread visceral disease. Here, we report the case of a 30-year-old female who presented to the hospital with back pain, low-grade fever, and easy bruising. She was found to be bicytopenic and in disseminated intravascular coagulopathy (DIC). Surprisingly, BM biopsy showed extensive involvement by metastatic malignant melanoma in the absence of visceral or brain metastasis. The unique presentation of this case and the challenge of management of a potentially treatable cancer in a critically ill patient are discussed, alongside a review of published cases of metastatic melanoma in the BM and an exploration of currently available treatment options. The excellent response of our patient to combined immune checkpoint inhibitors has yet to be paralleled in the available literature.

show abstract

Section: Discussionmentioning

confidence: 99%

Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

Gbadamosi

Ezekwudo

Nayak

et al. 2018

Case Reports in Immunology

View full text Add to dashboard Cite

show abstract

“…The categorization was conducted independently by two researchers (JB, TS); disagreements were discussed and remedied in a subsequent meeting. Secondly, the groups (1) -(3) and (6) were summarized as oncology expert domains and the groups (4), (5), and (7) were summarized as domains provided by the general public press. 'General public press' domains describe domains that do not primarily 4 address a particular subgroup of users such as patients or medical experts, but rather the general public.…”

Section: Grouping Of Websitesmentioning

confidence: 99%

“…Approvals of new effective therapies in the last decade have substantially expanded the treatment spectrum, especially for melanoma patients with metastatic disease. One of these treatment options is immunotherapy, whose application has resulted in pioneering response rates and significantly increased survival chances of melanoma patients [4][5][6].…”

Section: Introductionmentioning

confidence: 99%

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

et al. 2018

View full text Add to dashboard Cite

show abstract

“…We administrated ipilimumab to patients who showed disease progression while being treated with an anti‐PD‐1 antibody. In past reports, the objective response rates were 3.6–16% in advanced melanoma patients given an anti‐PD‐1 antibody followed by ipilimumab . However, ipilimumab therapy is reportedly used more frequently and produces more severe immune‐related adverse events (irAE) than nivolumab .…”

Section: Introductionmentioning

confidence: 99%

Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab

Muto¹,

Kitano

Tsutsumida

et al. 2019

The Journal of Dermatology

View full text Add to dashboard Cite

Melanoma is one of the most serious form of skin cancer. Nowadays, ipilimumab is used for advanced melanoma refractory to first‐line anti‐programmed death 1 (PD‐1) antibodies. Thirty patients (male : female ratio, 18:12; median age, 60.5 years) sequentially treated with ipilimumab after anti‐PD‐1 antibody (nivolumab or pembrolizumab), while 58 (male : female ratio, 27:31; median age, 66.5 years) with anti‐PD‐1 antibody only. The kind of therapy and schedules were as follows: nivolumab, 2 mg/kg at 3‐week intervals or at 3 mg/kg every 2 week; pembrolizumab, 2 mg/kg every 3 weeks; ipilimumab, 3 mg/kg at 3‐week intervals for four doses. The sequential therapy was selected for the patients with disease progression and/or recovered from severe (immune‐related [ir]) adverse events (AE) after PD‐1 blockade monotherapy. We evaluated multiple parameters and analyzed their relevance to overall survival (OS). The best objective response rate was 6.7% in sequential ipilimumab treatment. Median OS was 163 days (range, 16–489). Baseline absolute lymphocyte count (ALC) and performance status (PS) before sequential ipilimumab were associated with OS in univariate analyses. Baseline PS and irAE within 6 weeks after ipilimumab administration showed significant differences on multivariate analysis. Prior to first‐line PD‐1 blockade, these parameters were not associated with OS. The other factors (i.e. age, sex, number of doses, absolute neutrophil counts, neutrophil : lymphocyte ratio, lactate dehydrogenase and C‐reactive protein) were not associated with OS. [Correction added on 17 April 2019, after first online publication: ‘not related to OS' has been amended to ‘not associated with OS’.] Ipilimumab as sequential therapy did not appear to improve OS and was associated with more severe irAE than PD‐1 blockade monotherapy. We need to carefully consider treating patients with poor PS and low ALC.

show abstract

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma

Cited by 151 publications

References 23 publications

Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

Effective Immunotherapy in Bone Marrow Metastatic Melanoma Presenting with Disseminated Intravascular Coagulopathy

Exploring the Most Visible German Websites on Melanoma Immunotherapy: A Web-Based Analysis

Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab

Contact Info

Product

Resources

About